Postoperative adjuvant antiviral therapy for hepatitis B/C virus-related hepatocellular carcinoma: A meta-analysis

World Journal of Gastroenterology

Volumn 16, Issue 23, 2010, Pages 2931-2942

  Miao, Ruo Yu ^a   Zhao, Hai Tao ^a   Yang, Hua Yu ^a   Mao, Yi Lei ^a   Lu, Xin ^a   Zhao, Yi ^b   Liu, Chang Ning ^b   Zhong, Shou Xian ^a   Sang, Xin Ting ^a   Huang, Jie Fu ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b INSTITUTE OF COMPUTING TECHNOLOGY   (China)

Author keywords

Antiviral therapy; Hepatitis B virus; Hepatitis C virus; Hepatocellular carcinoma; Recurrence; Survival

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; ENTECAVIR; LAMIVUDINE; NUCLEOSIDE DERIVATIVE; PEGINTERFERON ALPHA2B; RECOMBINANT ALPHA INTERFERON; RECOMBINANT BETA INTERFERON; RECOMBINANT INTERFERON; RIBAVIRIN; INTERFERON;

ADJUVANT THERAPY; ANTIVIRAL THERAPY; ARTICLE; CANCER MORTALITY; CANCER RECURRENCE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CONTROL; DRUG EFFICACY; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER RESECTION; LIVER TRANSPLANTATION; META ANALYSIS; MICROWAVE THERAPY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERCUTANEOUS MICROWAVE COAGULATION THERAPY; POSTOPERATIVE CARE; RADIOFREQUENCY ABLATION; RISK REDUCTION; SURVIVAL RATE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION; ADJUVANT CHEMOTHERAPY; CARCINOMA, HEPATOCELLULAR; COMPLICATION; CONTROLLED CLINICAL TRIAL (TOPIC); HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; LIVER NEOPLASMS; MORTALITY; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SURVIVAL;

ANTIVIRAL AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOTHERAPY, ADJUVANT; CONTROLLED CLINICAL TRIALS AS TOPIC; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; INTERFERONS; LIVER NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL ANALYSIS;

EID: 77954266287     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i23.2931     Document Type: Article

References (38)

1. Kardinal CG, Moertel CG, Wieand HS, Schutt AJ, O'Connell MJ, Wright K, Wiesenfeld M, Tschetter LK, Krook JE. Combined doxorubicin and alpha-interferon therapy of advanced hepatocellular carcinoma. Cancer 1993; 71: 2187-2190
2. Patt YZ, Hassan MM, Lozano RD, Brown TD, Vauthey JN, Curley SA, Ellis LM. Phase II trial of systemic continuous fluorouracil and subcutaneous recombinant interferon Alfa-2b for treatment of hepatocellular carcinoma. J Clin Oncol 2003; 21: 421-427
3. Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, Gardner S, Gray DF, Schiff ER. Histological outcome during long-term lamivudine therapy. Gastroenterology 2003; 124: 105-117
4. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, Chang TT, Kitis G, Rizzetto M, Marcellin P, Lim SG, Goodman Z, Ma J, Brosgart CL, Borroto-Esoda K, Arterburn S, Chuck SL. Longterm therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006; 131: 1743-1751
5. Papatheodoridis GV, Dimou E, Dimakopoulos K, Manolakopoulos S, Rapti I, Kitis G, Tzourmakliotis D, Manesis E, Hadziyannis SJ. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129
6. Bae SH, Yoon SK, Choi JY, Jang JW, Cho SH, Yang JM, Han NI, Ahn BM, Chung KW, Sun HS. Timing of lamivudine administration according to Child class in patients with decompensated cirrhosis. J Gastroenterol Hepatol 2005; 20: 1527-1532
7. Tseng PL, Lu SN, Tung HD, Wang JH, Changchien CS, Lee CM. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis. J Viral Hepat 2005; 12: 386-392
8. Omata M, Yoshida H, Shiratori Y. Prevention of hepatocellular carcinoma and its recurrence in chronic hepatitis C patients by interferon therapy. Clin Gastroenterol Hepatol 2005; 3: S141-S143
9. Shiratori Y, Shiina S, Teratani T, Imamura M, Obi S, Sato S, Koike Y, Yoshida H, Omata M. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003; 138: 299-306
10. Shuqun C, Mengchao W, Han C, Feng S, Jiahe Y, Wenming C, Zhengfeng Y, Yuxiang Z, Peijun W. Antiviral therapy using lamivudine and thymosin alpha1 for hepatocellular carcinoma coexisting with chronic hepatitis B infection. Hepatogastroenterology 2006; 53: 249-252
11. Cheng SQ, Wu MC, Chen H, Shen F, Yang JH, Cong WM, Zhao YX, Wang PJ. [Anti-viral therapy using lamivudine and thymosin is helpful to prevent recurrence in hepatocellular carcinoma with coexisting active hepatitis B] Zhonghua Zhongliu Zazhi 2005; 27: 114-116
12. Nishiguchi S, Tamori A, Kubo S. Effect of long-term postoperative interferon therapy on intrahepatic recurrence and survival rate after resection of hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 71-75
13. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Kinoshita H. Randomized clinical trial of long-term outcome after resection of hepatitis C virus-related hepatocellular carcinoma by postoperative interferon therapy. Br J Surg 2002; 89: 418-422
14. Kubo S, Nishiguchi S, Hirohashi K, Tanaka H, Shuto T, Yamazaki O, Shiomi S, Tamori A, Oka H, Igawa S, Kuroki T, Kinoshita H. Effects of long-term postoperative interferonalpha therapy on intrahepatic recurrence after resection of hepatitis C virus-related hepatocellular carcinoma. A randomized, controlled trial. Ann Intern Med 2001; 134: 963-967
15. Ji J, Shi J, Budhu A, Yu Z, Forgues M, Roessler S, Ambs S, Chen Y, Meltzer PS, Croce CM, Qin LX, Man K, Lo CM, Lee J, Ng IO, Fan J, Tang ZY, Sun HC, Wang XW. MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med 2009; 361: 1437-1447
16. Lo CM, Liu CL, Chan SC, Lam CM, Poon RT, Ng IO, Fan ST, Wong J. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 2007; 245: 831-842
17. Sun HC, Tang ZY, Wang L, Qin LX, Ma ZC, Ye QH, Zhang BH, Qian YB, Wu ZQ, Fan J, Zhou XD, Zhou J, Qiu SJ, Shen YF. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 2006; 132: 458-465
18. Takahashi S, Kudo M, Chung H, Inoue T, Nagashima M, Kitai S, Tatsumi C, Minami Y, Ueshima K, Fukunaga T, Haji S. Outcomes of nontransplant potentially curative therapy for early-stage hepatocellular carcinoma in Child-Pugh stage A cirrhosis is comparable with liver transplantation. Dig Dis 2007; 25: 303-309
19. Miyaguchi S, Watanabe T, Takahashi H, Nakamura M, Saito H, Ishii H. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002; 49: 724-729
20. Suou T, Mitsuda A, Koda M, Matsuda H, Maruyama S, Tanaka H, Kishimoto Y, Kohno M, Hirooka Y, Kawasaki H. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001; 20: 301-311
21. Kubo S, Takemura S, Uenishi T, Yamamoto T, Ohba K, Ogawa M, Hai S, Ichikawa T, Kodai S, Shinkawa H, Tanaka H. Second hepatic resection for recurrent hepatocellular carcinoma in patients with chronic hepatitis C. World J Surg 2008; 32: 632-638
22. Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5343-5350
23. Jeong S, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K. Low-dose intermittent interferon-alpha therapy for HCVrelated liver cirrhosis after curative treatment of hepatocellular carcinoma. World J Gastroenterol 2007; 13: 5188-5195
24. Akamatsu M, Yoshida H, Shiina S, Teratani T, Obi S, Tateishi R, Mine N, Kondo Y, Kawabe T, Omata M. Sustained viral response prolonged survival of patients with C-viral hepatocellular carcinoma. Liver Int 2006; 26: 536-542
25. Hung CH, Lee CM, Wang JH, Tung HD, Chen CH, Lu SN. Antiviral therapy after non-surgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005; 20: 1553-1559
26. Sakaguchi Y, Kudo M, Fukunaga T, Minami Y, Chung H, Kawasaki T. Low-dose, long-term, intermittent interferonalpha- 2b therapy after radical treatment by radiofrequency ablation delays clinical recurrence in patients with hepatitis C virus-related hepatocellular carcinoma. Intervirology 2005; 48: 64-70
27. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Suzuki Y, Suzuki F, Tsubota A, Chayama K, Murashima N, Kumada H. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor-A prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000; 32: 228-232
28. Kuzuya T, Katano Y, Kumada T, Toyoda H, Nakano I, Hirooka Y, Itoh A, Ishigami M, Hayashi K, Honda T, Goto H. Efficacy of antiviral therapy with lamivudine after initial treatment for hepatitis B virus-related hepatocellular carcinoma. J Gastroenterol Hepatol 2007; 22: 1929-1935
29. Piao CY, Fujioka S, Iwasaki Y, Fujio K, Kaneyoshi T, Araki Y, Hashimoto K, Senoh T, Terada R, Nishida T, Kobashi H, Sakaguchi K, Shiratori Y. Lamivudine treatment in patients with HBV-related hepatocellular carcinoma--using an untreated, matched control cohort. Acta Med Okayama 2005; 59: 217-224
30. Someya T, Ikeda K, Saitoh S, Kobayashi M, Hosaka T, Sezaki H, Akuta N, Suzuki F, Suzuki Y, Arase Y, Kumada H. Interferon lowers tumor recurrence rate after surgical resection or ablation of hepatocellular carcinoma: a pilot study of patients with hepatitis B virus-related cirrhosis. J Gastroenterol 2006; 41: 1206-1213
31. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 2006; 44: 1543-1554
32. Lin SM, Lin CJ, Hsu CW, Tai DI, Sheen IS, Lin DY, Liaw YF. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004; 100: 376-382
33. Kubo S, Nishiguchi S, Hirohashi K, Shuto T, Kuroki T, Minamitani S, Ikebe T, Yamamoto T, Wakasa K, Kinoshita H. Clinicopathological criteria for multicentricity of hepatocellular carcinoma and risk factors for such carcinogenesis. Jpn J Cancer Res 1998; 89: 419-426
34. Shiratori Y, Imazeki F, Moriyama M, Yano M, Arakawa Y, Yokosuka O, Kuroki T, Nishiguchi S, Sata M, Yamada G, Fujiyama S, Yoshida H, Omata M. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med 2000; 132: 517-524
35. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol Suppl 2003; 47-51
36. Dunk AA, Ikeda T, Pignatelli M, Thomas HC. Human lymphoblastoid interferon. In vitro and in vivo studies in hepatocellular carcinoma. J Hepatol 1986; 2: 419-429
37. Ghany MG, Doo EC. Antiviral resistance and hepatitis B therapy. Hepatology 2009; 49: S174-S184
38. Kim BK, Park JY, Kim do Y, Kim JK, Kim KS, Choi JS, Moon BS, Han KH, Chon CY, Moon YM, Ahn SH. Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int 2008; 28: 393-401